🔗 Share this article

While the US continues making historic revisions to its vaccine guidelines, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccines during the pandemic and has focused upon alleged deaths after Covid immunization in her recent position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Program

Public health authorities were set to announce sweeping changes to the childhood vaccination calendar in December, aligning the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US at odds with many the world with insufficient data for benefit. The announcement has been delayed until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to present at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to head the office this year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine divisions as Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has frequently advocated for discontinuing specific childhood shot schedules in the US to become more like Denmark, a nation with nationalized medicine and a population approximately the population of Wisconsin’s.

To date comments, she has persisted in emphasizing on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Qualifications

Dr. Høeg has no obvious background in medication creation, approval processes or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in running a large organization. She lacks background in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the science of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who headed the center have had.”

The drug center has an immense portfolio at the agency, she pointed out.

“Everybody just zeroes in on the new drug program, but the off-patent medication office approves a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and other areas, and each of these must be managed,” Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major administrative aspect to the position, which oversees over 5,000 employees. “It is a massive management job, if you perform it correctly,” Woodcock concluded.

Response and Contentious Policies

Regarding concerns about Høeg’s fitness for the role and whether this appointment represents increased cooperation among FDA leaders on vaccines, a representative responded that the “questions are based on inaccurate assumptions”.

“Her resume aligns with the duties of her job,” the representative explained, noting the period Dr. Høeg spent advising the agency head on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a disputed rapid medication authorization process that allegedly worried her predecessors. “By what process are these therapies being picked for this voucher program? Who takes the calls?” Howard questioned. “There is a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards laxer regulations of most medications, with the exception of shots.”

Documented History on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if concerning, history, some experts observe. She released a study using unverified public submissions to assess the frequency of heart inflammation following Covid immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the new federal leadership encompassed revising regulations for novel immunizations and ending “non-essential” vaccines, she remarked post-election on a audio program. At the agency, Høeg has allegedly proposed excluding adolescent males from receiving Covid vaccinations.

“She is an complete ideologue who commences with her conclusions and tailors the evidence to accommodate the data in a highly misleading, dishonest manner,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg joined other skeptics, {like|